Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Payables (2016 - 2025)

Surgery Partners (SGRY) has disclosed Payables for 12 consecutive years, with $208.7 million as the latest value for Q4 2025.

  • Quarterly Payables changed 0.0% to $208.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $208.7 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $208.7 million for FY2025, 0.0% changed from the prior year.
  • Payables hit $208.7 million in Q4 2025 for Surgery Partners, up from $174.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $208.7 million in Q4 2024 to a low of $96.0 million in Q1 2021.
  • Historically, Payables has averaged $151.7 million across 5 years, with a median of $150.2 million in 2022.
  • Biggest five-year swings in Payables: fell 10.11% in 2021 and later surged 32.32% in 2024.
  • Year by year, Payables stood at $124.9 million in 2021, then rose by 21.38% to $151.6 million in 2022, then rose by 13.32% to $171.8 million in 2023, then rose by 21.48% to $208.7 million in 2024, then changed by 0.0% to $208.7 million in 2025.
  • Business Quant data shows Payables for SGRY at $208.7 million in Q4 2025, $174.6 million in Q3 2025, and $174.9 million in Q2 2025.